Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy

Natalia V Danilova,1,2 Zhomart R Kalzhanov,3 Nina A Nefedova,2 Pavel G Mal’kov,2 Ioannis P Kosmas,1,4 Marina Y Eliseeva,1,5 Ospan A Mynbaev1,5,6 1International Translational Medicine and Biomodeling Research Team, MIPT Center for Human Physiology, Laboratory of Cellular and Mole...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Danilova NV, Kalzhanov ZR, Nefedova NA, Mal’kov PG, Kosmas IP, Eliseeva MY, Mynbaev OA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0cf9e39db1804671afb81be4c984915b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0cf9e39db1804671afb81be4c984915b
record_format	dspace
spelling	oai:doaj.org-article:0cf9e39db1804671afb81be4c984915b2021-12-02T01:34:05ZDocetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy1178-2013https://doaj.org/article/0cf9e39db1804671afb81be4c984915b2015-03-01T00:00:00Zhttp://www.dovepress.com/docetaxel-loaded-solid-lipid-nanoparticles-as-a-basis-for-a-targeted-a-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Natalia V Danilova,1,2 Zhomart R Kalzhanov,3 Nina A Nefedova,2 Pavel G Mal’kov,2 Ioannis P Kosmas,1,4 Marina Y Eliseeva,1,5 Ospan A Mynbaev1,5,6 1International Translational Medicine and Biomodeling Research Team, MIPT Center for Human Physiology, Laboratory of Cellular and Molecular Technologies, Moscow Institute of Physics and Technology, State University, 2Department of Physiology and Basic Pathology, Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia; 3Department of Human Metabolism, Academic Unit of Reproductive and Developmental Medicine, Sheffield University, Sheffield, UK; 4Department of Obstetrics and Gynecology, Ioannina State General Hospital G Chatzikosta, Ioannina, Greece; 5Department of Obstetrics, Gynecology and Reproductive Medicine, Peoples’ Friendship University of Russia, 6Laboratory of Immunology, Moscow State University of Medicine and Dentistry named after AI Evdokimov, Moscow, Russia The long-term survival rate of patients with breast cancer was improved by the application of systemic adjuvant chemotherapy,1 although the primary breast cancer treatment strategy consists of mastectomy with lymphadenectomy and radiotherapy followed by breast reconstruction.2–5 Unfortunately, most adjuvant chemotherapeutic agents trigger major side effects.1,6 Therefore, we have read with great interest an article in the International Journal of Nanomedicine on the design of docetaxel-loaded solid lipid nanoparticles (DSNs) aimed at reducing the systemic toxicity of standardized docetaxel treatment.7 Read the original article Danilova NVKalzhanov ZRNefedova NAMal’kov PGKosmas IPEliseeva MYMynbaev OADove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 2417-2421 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Danilova NV Kalzhanov ZR Nefedova NA Mal’kov PG Kosmas IP Eliseeva MY Mynbaev OA Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
description	Natalia V Danilova,1,2 Zhomart R Kalzhanov,3 Nina A Nefedova,2 Pavel G Mal’kov,2 Ioannis P Kosmas,1,4 Marina Y Eliseeva,1,5 Ospan A Mynbaev1,5,6 1International Translational Medicine and Biomodeling Research Team, MIPT Center for Human Physiology, Laboratory of Cellular and Molecular Technologies, Moscow Institute of Physics and Technology, State University, 2Department of Physiology and Basic Pathology, Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia; 3Department of Human Metabolism, Academic Unit of Reproductive and Developmental Medicine, Sheffield University, Sheffield, UK; 4Department of Obstetrics and Gynecology, Ioannina State General Hospital G Chatzikosta, Ioannina, Greece; 5Department of Obstetrics, Gynecology and Reproductive Medicine, Peoples’ Friendship University of Russia, 6Laboratory of Immunology, Moscow State University of Medicine and Dentistry named after AI Evdokimov, Moscow, Russia The long-term survival rate of patients with breast cancer was improved by the application of systemic adjuvant chemotherapy,1 although the primary breast cancer treatment strategy consists of mastectomy with lymphadenectomy and radiotherapy followed by breast reconstruction.2–5 Unfortunately, most adjuvant chemotherapeutic agents trigger major side effects.1,6 Therefore, we have read with great interest an article in the International Journal of Nanomedicine on the design of docetaxel-loaded solid lipid nanoparticles (DSNs) aimed at reducing the systemic toxicity of standardized docetaxel treatment.7 Read the original article
format	article
author	Danilova NV Kalzhanov ZR Nefedova NA Mal’kov PG Kosmas IP Eliseeva MY Mynbaev OA
author_facet	Danilova NV Kalzhanov ZR Nefedova NA Mal’kov PG Kosmas IP Eliseeva MY Mynbaev OA
author_sort	Danilova NV
title	Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
title_short	Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
title_full	Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
title_fullStr	Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
title_full_unstemmed	Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
title_sort	docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/0cf9e39db1804671afb81be4c984915b
work_keys_str_mv	AT danilovanv docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy AT kalzhanovzr docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy AT nefedovana docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy AT malkovpg docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy AT kosmasip docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy AT eliseevamy docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy AT mynbaevoa docetaxelloadedsolidlipidnanoparticlesasabasisforatargetedanddosesparingpersonalizedbreastcancertreatmentstrategy
_version_	1718402998717120512

Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy

Ejemplares similares